Home › FDA Decisions › AMRX 2025-01-23

AMRX FDA Decision Approved · 2025-01-23

Updated September 3, 2026·next FDA decision on the calendar

Price into the decision (T-120)

Daily close, T-120 (8/8/24) through T+5. Run-up high $9.25 on 11/19/24, low $6.7 on 8/13/24 (T-120 to T-1). FDA decision 1/23/25. Historical price action, not a forecast.

Decision facts

FDA decision date2025-01-23

DrugEverolimus

IndicationTuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA)

Outcome✓ Approvedprimary-sourced

Decision-day move+3.4%

T-120 run-up (low→high)+9.0% ($7.69→$9.25)

ValidationVerified 2026-08-12: Drugs@FDA, application ANDA217640, action date 2025-01-28

Market-cap tierMicro

Cohort decision-day move (history)4.6% median (n=308)

Cohort move is the historical median absolute decision-day move for this market-cap tier across our run-up study. History, not a prediction.

See the full 2026 PDUFA calendar →

Questions

Was Everolimus approved by the FDA?

Yes. The FDA approved the application for Everolimus on January 23, 2025. The primary source is linked on this page.

What was Everolimus under FDA review for?

The application covered Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA). The FDA approved the application on January 23, 2025.

How did AMRX stock react to the FDA decision?

On the decision day AMRX moved +3.4%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.